natgillin/translations-raw huggingface dataset:
More serious side effects include pneumonia (which may affect up to 1 in 10 people). 
Resnejši neželeni učinki vključujejo pljučnico (ki se lahko pojavi pri največ 1 bolniku od 10).
What measures are being taken to ensure the safe and effective use of Trelegy Ellipta? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Trelegy Ellipta?
Trelegy Ellipta is used for maintenance (regular) treatment on a daily basis. 
Zdravilo Trelegy Ellipta se uporablja za vzdrževalno (redno) vsakodnevno zdravljenje.
This compares with an average reduction of 29 ml seen in patients taking the combination of budesonide and formoterol over the same period. 
Ta vrednost se je povprečno zmanjšala za 29 ml pri bolnikih, ki so v enakem obdobju jemali kombinacijo budezonida in formoterola.
Trelegy Ellipta (fluticasone furoate / umeclidinium bromide / vilanterol) 
Trelegy Ellipta (flutikazonfuroat/umeklidinijev bromid/vilanterol)
In this study, Trelegy Ellipta reduced the rate of moderate and severe exacerbations over one year by 15% compared with treatment with vilanterol and fluticasone furoate, and by 25% compared with treatment with vilanterol and umeclidinium bromide. 
V tej študiji je zdravilo Trelegy Ellipta zmanjšalo stopnjo zmernih in resnih poslabšanj bolezni v enem letu za 15 % v primerjavi z zdravljenjem z vilanterolom in flutikazonfuroatom in za 25 % v primerjavi z zdravljenjem z vilanterolom in umeklidinijevim bromidom.
It works by attaching to beta-2 receptors in some types of muscle cells. 
Deluje tako, da se veže na receptorje beta-2 v nekaterih vrstah mišičnih celic.
The most common side effects with Trelegy Ellipta (which may affect up to 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat), headache and upper respiratory tract infection (nose and throat infection). 
Najpogostejši neželeni učinki zdravila Trelegy Ellipta (ki se lahko pojavijo pri največ 1 bolniku od 10) so nazofaringitis (vnetje nosu in žrela), glavobol in okužba zgornjih dihal (okužba nosu in grla).
Patients treated with Trelegy Ellipta also reported improved health compared with those treated with the comparator treatment. 
Bolniki, ki so jemali zdravilo Trelegy Ellipta, so poročali tudi o izboljšanju zdravja v primerjavi z bolniki, ki so bili zdravljeni s primerjalnim zdravilom.
It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol. 
Vsebuje učinkovine flutikazonfuroat, umeklidinijev bromid in vilanterol.
As for all medicines, data on the use of Trelegy Ellipta are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Trelegy Ellipta stalno spremljajo.
Side effects reported with Trelegy Ellipta are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Trelegy Ellipta, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trelegy Ellipta have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Trelegy Ellipta upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Long-acting beta-2 agonists widen the airways; corticosteroids reduce inflammation in the airways and lungs; and muscarinic receptor antagonists cause the muscles of the airways to relax. 
Dolgodelujoči agonisti adrenergičnih receptorjev beta-2 razširjajo dihalne poti; kortikosteroidi zmanjšujejo vnetje v dihalnih poteh in pljučih; antagonisti muskarinskih receptorjev pa povzročajo, da se mišice dihal sprostijo.
Other information about Trelegy Ellipta 
Druge informacije o zdravilu Trelegy Ellipta
Trelegy Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). 
Trelegy Ellipta je zdravilo, ki se uporablja za lajšanje simptomov zmerne do hude kronične obstruktivne pljučne bolezni (KOPB).
An overview of Trelegy Ellipta and why it is authorised in the EU 
Pregled zdravila Trelegy Ellipta in zakaj je odobreno v EU
Umeclidinium bromide is a muscarinic receptor antagonist. 
Umeklidinijev bromid je antagonist muskarinskih receptorjev.
Vilanterol is a long-acting beta-2 agonist. 
Vilanterol je dolgodelujoči agonist adrenergičnih receptorjev beta-2.
This reduces the release of substances involved in the inflammation process, such as histamine, thereby reducing inflammation and helping to keep the airways clear and allowing the patient to breathe more easily. 
S tem se zmanjša sproščanje snovi, ki sodelujejo v procesu vnetja, na primer histamina, zato se zmanjša vnetje, kar pripomore k ohranjanju prehodnosti dihalnih poti in bolniku olajša dihanje.
Regarding the safety profile of the medicine, the most frequent side effects reported with Trelegy Ellipta were similar to those with the individual active substances of the medicine and are well known. 
Glede varnostnega profila zdravila Trelegy Ellipta so bili najpogostejši neželeni učinki, o katerih so poročali pri uporabi tega zdravila, podobni kot pri posameznih učinkovinah zdravila in so dobro znani.
Why is Trelegy Ellipta authorised in the EU? 
Zakaj je bilo zdravilo Trelegy Ellipta odobreno v EU?
It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors (targets) in various types of immune cells. 
Deluje podobno kot kortikosteroidni hormoni, ki naravno nastajajo v telesu, pri čemer se veže na receptorje (prijemališča) v različnih vrstah imunskih celic in tako zmanjša dejavnost imunskega sistema.
Trelegy Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a longacting muscarinic antagonist. 
Zdravilo Trelegy Ellipta se uporablja pri odraslih, pri katerih bolezen ni dovolj dobro nadzorovana s kombinacijo inhalacijskih zdravil, ki jo sestavljata dolgodelujoči agonist adrenergičnih receptorjev beta-2 in kortikosteroid ali dolgodelujoči muskarinski antagonist.
What is Trelegy Ellipta and what is it used for? 
Kaj je zdravilo Trelegy Ellipta in za kaj se uporablja?
Trelegy Ellipta contains three active substances, which work in different ways to widen the airways and improve breathing in COPD. 
Zdravilo Trelegy Ellipta vsebuje tri učinkovine, ki različno delujejo na širjenje dihalnih poti in izboljšanje dihanja pri KOPB.
What benefits of Trelegy Ellipta have been shown in studies? 
Kakšne koristi je zdravilo Trelegy Ellipta izkazalo v študijah?
What are the risks associated with Trelegy Ellipta? 
Kakšna tveganja so povezana z zdravilom Trelegy Ellipta?
Another study involving 1,810 patients whose COPD was not satisfactorily controlled with a daily maintenance treatment for their COPD found Trelegy Ellipta more effective at improving patients' breathing than an inhaled combination of budesonide, a corticosteroid, and formoterol, a long-acting beta-2 agonist. 
Druga študija s 1 810 bolniki, pri katerih KOPB ni bila zadostno nadzorovana z dnevnim vzdrževalnim zdravljenjem, je pokazala, da je zdravilo Trelegy Ellipta pri izboljšanju dihanja bolnikov učinkovitejše od inhalirane kombinacije budezonida, kortikosteroida in formoterola, dolgodelujočega agonista adrenergičnih receptorjev beta2.
It is available as an inhalation powder, which the patient inhales through the mouth using a portable inhaler device; the patient should inhale the medicine once a day at around the same time each day. 
Na voljo je kot prašek za inhalacijo, ki ga bolnik inhalira skozi usta s prenosnim inhalatorjem; bolnik inhalira zdravilo enkrat na dan ob približno isti uri vsak dan. Za več informacij glede uporabe zdravila Trelegy Ellipta glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
For the full list of side effects and restrictions with Trelegy Ellipta, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Trelegy Ellipta glejte navodilo za uporabo.
When umeclidinium bromide is inhaled, it causes the muscles of the airways to relax. 
Inhaliranje umeklidinijevega bromida vpliva na sproščanje mišic dihalnih poti.
Trelegy Ellipta improves lung function as well as the quality of life of patients with moderate to severe COPD. 
Zdravilo Trelegy Ellipta izboljšuje delovanje pljuč in kakovost življenja bolnikov z zmerno do hudo KOPB.
It works by blocking muscarinic receptors, which are involved in the contraction of muscles. 
Deluje tako, da zavira muskarinske receptorje, ki nadzorujejo krčenje mišic.
When inhaled, vilanterol activates the beta-2 receptors in the airways. 
Pri inhaliranju aktivira receptorje beta-2 v dihalnih poteh.
Trelegy Ellipta can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Trelegy Ellipta je le na recept.
How is Trelegy Ellipta used? 
Kako se zdravilo Trelegy Ellipta uporablja?
Trelegy Ellipta was shown to improve patients' breathing and reduce exacerbations (flare-ups) of the disease in 2 main studies. 
V dveh glavnih študijah je bilo dokazalo, da zdravilo Trelegy Ellipta izboljša bolnikovo dihanje in zmanjša poslabšanja (izbruhe) bolezni.
How does Trelegy Ellipta work? 
Kako zdravilo Trelegy Ellipta deluje?
A study compared Trelegy Ellipta with either vilanterol given with fluticasone furoate or vilanterol with umeclidinium bromide, in 10,355 patients with advanced COPD who were at risk of exacerbations and whose disease was not satisfactorily controlled with a daily maintenance treatment. 
V študiji, ki je vključevala 10 355 bolnikov z napredovalim KOPD, pri katerih je obstajalo tveganje za poslabšanje bolezni in pri katerih bolezen ni bila zadostno nadzorovana z dnevnim vzdrževalnim zdravljenjem, so zdravilo Trelegy Ellipta primerjali z vilanterolom v kombinaciji s flutikazonfuroatom ali vilanterolom v kombinaciji z umeklidinijevim bromidom.
These reactions are potentially serious and occasionally life threatening. 
Te reakcije so lahko resne in občasno življenjsko ogrožajoče.
To start, take one tablet daily. 
Za začetek vzemite eno tableto na dan.
The initial dose is one tablet (1-1.65 mg) per day at mealtime. 
Začetni odmerek je ena tableta (1-1,65 mg) na dan v času obroka.
<Or> 
<ali>
The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC. 
Informacije o zdravilu bodo pristojni organi države članice v sodelovanju z referenčno državo članico morda pozneje posodobili, kot je primerno, skladno s postopki iz Poglavja 4, Naslova III Direktive 2001/83/ES.
Your doctor will review and decide if you must stop the medication. 
Vaš zdravnik bo ocenil vaše stanje in presodil, ali morate prenehati jemati to zdravilo.
(see section 4.4 regarding the need for specialist monitoring requirements) 
(za informacije o potrebi po zahtevah specialističnega spremljanja glejte poglavje 4.4)
Then increase the dose gradually according to your doctor's instructions. 
Nato postopoma povečujte odmerek skladno z navodili zdravnika.
The medication must be stopped as soon as one of these symptoms or signs has been established. 
Z zdravljenjem je treba prenehati takoj, ko je ugotovljen kateri od teh simptomov ali znakov.
Discontinuation of the treatment should be done gradually (in 2 or 3 weeks). 
Prekinitev zdravljenja je treba izvesti postopno (v obdobju 2 do 3 tednov).
Before you take [Invented name] tell your doctor if: 
Preden boste vzeli zdravilo [izmišljeno ime], povejte zdravniku, če:
You notice numbness or tingling in your fingers and toes. 
opazite omrtvičenost ali ščemenje v prstih na rokah in nogah.
<[Invented name] contains lactose. 
<Zdravilo [izmišljeno ime] vsebuje laktozo.
Take the tablets during a meal with some drink. 
Tablete vzemite med obrokom, z nekaj tekočine.
The minimal duration of treatment before concluding failure is 2 months. 
Najkrajše trajanje zdravljenja pred sklepom o neuspehu je 2 meseca.
The existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the newly agreed wording as provided below. 
Obstoječe informacije o zdravilu se spremenijo (vstaviti, nadomestiti ali izbrisati besedilo, kot je ustrezno) tako, da vsebujejo dogovorjeno besedilo, kot je navedeno spodaj.
In between two treatments there should be an interval of 3-4 weeks in order to check whether you still need to take [Invented name]. 
Med dvema cikloma zdravljenja mora biti obdobje 3-4 tednov, da se lahko prepričate, ali še vedno potrebujete zdravilo [izmišljeno ime].
What you need to know before you take [Invented name] 
Kaj morate vedeti, preden boste vzeli zdravilo [izmišljeno ime]
Patients should be informed on the risk of fibrosis with methysergide therapy and should accept the need for periodic investigations as described below. 
Bolnike je treba seznaniti s tveganjem za fibrozo pri zdravljenju z metizergidom in sprejeti morajo potrebo po rednih preiskavah, kot je opisano spodaj.
The maximum dose should not exceed 6 mg per day. 
Največji odmerek ne sme preseči 6 mg na dan.
Valvular fibrosis may cause changes in cardiac function. 
Valvularna fibroza lahko povzroči spremembe srčne funkcije.
The dosage may be gradually increased in divided daily dose until the optimal dose is reached. 
Odmerjanje se sme postopoma povečevati v obliki razdeljenega dnevnega odmerka, dokler ni dosežen optimalen odmerek.
It is recommended to taper the dosage gradually over the last two to three weeks of a course of treatment, so as to prevent a rebound effect on headaches. 
Priporočeno je, da se odmerjanje v zadnjih dveh do treh tednih zdravljenja postopoma zmanjšuje, da se prepreči povratni učinek na glavobole.
The need to continue treatment should be re-assessed, and the optimal timing for reintroduction discussed with the patient. 
Potrebo po nadaljevanju zdravljenja je treba ponovno oceniti in se o najboljšem času za ponovno uvedbo zdravljenja pogovoriti z bolnikom.
An abrupt cessation of treatment is necessary in the event of a fibrotic reaction. 
Nenadna prekinitev zdravljenja je potrebna v primeru fibrotičnih reakcij.
[Invented name] belong to a group of medicines called antimigraine drugs. 
Zdravilo [izmišljeno ime] spada v skupino zdravil, ki jih imenujemo protimigrenska zdravila.
[Invented name] should not be used in children. 
Zdravila [izmišljeno ime] se ne sme uporabljati pri otrocih.
[Invented name] is not effective for treating a migraine attack that is already present. 
Zdravilo [izmišljeno ime] ni učinkovito pri zdravljenju migrenskega napada, ki je že prisoten.
Although symptoms may sometimes improve after cessation of therapy in some cases, fibrotic reactions may also persist. 
Čeprav se simptomi v nekaterih primerih po prenehanju zdravljenja izboljšajo, lahko fibrotične reakcije vztrajajo.
[Invented name] should not be used in the paediatric population. 
Zdravila [izmišljeno ime] se ne sme uporabljati pri pediatrični populaciji.
Edema and vasoconstriction of the large and small arteries can occur. 
Lahko pride do edema in vazokonstrikcije velikih in majhnih arterij.
Your doctor will perform some tests before the start of treatment and then every 6 months to ensure that you do not have or develop fibrosis (scarring within body organs). 
Zdravnik bo opravil nekaj preizkusov pred začetkom zdravljenja in nato vsakih 6 mesecev, da se prepriča, da nimate fibroze (brazgotinjenja v telesnih organih) oziroma da se ta ni pozneje razvila.
Methysergide treatment should be initiated and supervised by specialised physicians with experience in the treatment of migraine and cluster headache. 
Zdravljenje z metizergidom morajo začeti in nadzorovati specializirani zdravniki z izkušnjami z zdravljenjem migrene in glavobola v rafalih.
Nausea and vomiting may occur, but these undesirable effects are often less severe if [Invented name] is taken at mealtime. 
Lahko pride do navzee in bruhanja, vendar so ti neželeni učinki pogosto manj hudi, če se zdravilo [izmišljeno ime] jemlje v času obroka.
Serious intolerance or contra-indication to a first line drug is regarded as treatment failure. 
Huda intoleranca na zdravilo prvega reda ali kontraindikacija nanj velja za neuspeh zdravljenja.
[Invented name] is taken by people who get severe migraines, with or without an aura, that affect their ability to go about their normal lives. 
Zdravilo [izmišljeno ime] jemljejo ljudje, ki imajo hude migrene z avro ali brez nje, ki prizadenejo njihovo zmožnost za normalno življenje.
The treatment should be stopped in patients who have not responded adequately in the first 2-3 months. 
Pri bolnikih, ki se v prvih 2-3 mesecih ne odzovejo v zadostni meri, je treba z zdravljenjem prenehati.
[Invented name] is to be used only following unsuccessful treatment with other standard classes of drugs (see section 4.4) after sufficient treatment duration (at least 4 months) at the maximal tolerated dose. 
Zdravilo [izmišljeno ime] se sme uporabljati le po neuspešnem zdravljenju z drugimi standardnimi razredi zdravil (glejte poglavje 4.4) po zadostnem trajanju zdravljenja (najmanj 4 mesece) z največjim toleriranim odmerkom.
[This section should be amended to reflect the following wording] 
[To poglavje je treba spremeniti tako, da vsebuje naslednje besedilo.]
The duration of continuous administration must not exceed six months because of the risk of fibrosis (see section 4.8). 
Zaradi tveganja za fibrozo trajanje neprekinjene uporabe ne sme preseči šestih mesecev (glejte poglavje 4.8).
Take special care with [Invented name] 
Bodite posebej previdni pri uporabi zdravila [izmišljeno ime]
For chronic cluster headache, the therapeutic dose would normally be 6 mg but a higher dose may sometimes be required. 
Pri kroničnem glavobolu v rafalih je običajen terapevtski odmerek 6 mg, vendar je včasih lahko potreben večji odmerek.
• Prophylactic treatment of episodic and chronic cluster headache in adults. 
• Profilaktično zdravljenje epizodnega in kroničnega glavobola v rafalih pri odraslih.
It is taken regularly as a preventative measure to reduce how often they get these headaches. 
To zdravilo se jemlje redno kot preventivni ukrep za zmanjšanje pogostosti teh glavobolov.
You must not take methysergide continuously (without a break) for longer than six months. 
Metizergida ne smete neprekinjeno (brez odmora) jemati več kot šest mesecev.
There have been isolated reports of myocardial infarct, especially in patients who do not pay attention to the contraindications regarding coronary disorders or the use of vasoconstrictive medications. 
Obstajajo osamljena poročila o miokardnem infarktu, še posebej pri bolnikih, ki niso pozorni na kontraindikacije v zvezi s koronarnimi boleznimi ali uporabo vazokonstriktivnih zdravil.
The tests will include a heart ultrasound, tests on how well your lungs are functioning and an abdominal scan such as a MRI. 
Ti preizkusi bodo vključevali ultrazvok srca, preizkuse tega, kako dobro delujejo vaša pljuča, in slikanje trebušnega predela, kot je preiskava MRI.
An initial screen must be performed prior to commencing methysergide therapy to exclude patients with pre-existent fibrosis or any other pathology that might put them at increased risk of developing fibrosis. 
Pred začetkom zdravljenja z metizergidom je treba opraviti začetno presejanje, da se izloči bolnike z že obstoječo fibrozo ali katero koli drugo patologijo, ki bi jih lahko izpostavila povečanemu tveganju za razvoj fibroze.
Heart valve fibrosis may cause increased heart rate, swelling in the hands and feet and can be identified by clinical examination. 
Fibroza srčne zaklopke lahko povzroči povišan srčni utrip ter zatekanje dlani in stopal, ugotoviti pa jo je mogoče s kliničnim pregledom.
- For prophylactic treatment of severe intractable migraine a number of other classes of treatment may be considered (e.g. beta-blockers, anticonvulsivants, calcium channel blocker or tricyclic antidepressants). 
- Pri profilaktičnem zdravljenju hude neobvladljive migrene lahko pridejo v poštev številni drugi razredi zdravil (npr. zaviralci beta receptorjev, antikonvulzivi, zaviralci kalcijevih kanalov ali triciklični antidepresivi).
Once treatment is commenced the patient must be examined for occurrence of fibrosis at 6-monthly intervals, this examination should include a reassessment of the benefit: risk balance in the individual patient. 
Po začetku zdravljenja je treba bolnika zaradi možnosti pojava fibroze pregledovati v 6-mesečnih intervalih, ti pregledi pa morajo vključevati ponovno oceno razmerja med koristmi in tveganji pri posameznem bolniku.
• Prophylactic treatment of severe intractable migraine (with or without aura) with functional disability in adults. 
• Profilaktično zdravljenje hude neobvladljive migrene (z avro ali brez nje) s funkcionalno nezmožnostjo pri odraslih.
Fibrotic reactions have been reported, especially of the pleura and retro-peritoneum, and also of the pericardium and cardiac valves. 
Poročali so o fibrotičnih reakcijah, še posebej plevre in retroperitoneja ter tudi perikardija in srčnih zaklopk.
However, it should only be used after at least two other types of medication for treating this type of headache have been tried for at least 2 months and failed to adequately treat the cluster headaches. 
Vendar pa ga smejo uporabiti šele potem, ko so jemali vsaj dve drugi vrsti zdravil za zdravljenje te vrste glavobola, in sicer vsaj 2 meseca, a ta zdravila niso v zadovoljivi meri ozdravila glavobolov v rafalih.
- For prophylactic treatment of episodic and chronic cluster headache at least two other classes of treatment should be considered first (e.g. verapamil, topiramate or lithium). 
- Pri profilaktičnem zdravljenju epizodnega in kroničnega glavobola v rafalih je treba prej razmisliti o uporabi vsaj dveh drugih razredov zdravil (npr. verapamil, topiramat ali litij).
If symptoms suggestive of a fibrosis occur, treatment with methysergide should be discontinued unless an alternative aetiology is confirmed. 
Če nastopijo simptomi, ki kažejo na fibrozo, je treba zdravljenje z metizergidom prekiniti, razen če je potrjena druga etiologija.
Nausea and vomiting, particularly if [Invented name] is taken outside meals. 
Siljenje na bruhanje in bruhanje, še posebej, če zdravila [izmišljeno ime] ne jemljete z obroki.
It is taken regularly as a preventative measure to reduce how often they get the migraines. 
To zdravilo se jemlje redno kot preventivni ukrep za zmanjšanje pogostosti migren.
[Invented name] should not be used to stop a headache once it has started. 
Zdravila [izmišljeno ime] ne smete uporabiti zato, da bi ustavili glavobol, ki se je že začel.
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflets 
Dopolnitev ustreznih poglavij v povzetkih glavnih značilnosti zdravil in navodilih za uporabo
Patients should have failed at least 2 classes of drugs before starting methysergide (see section 4.4). 
Pred začetkom zdravljenja z metizergidom mora pri bolnikih priti do neuspeha z najmanj 2 razredoma zdravil (glejte poglavje 4.4.).
Cardiac and vascular disorders 
Srčne in žilne bolezni
Valvular fibrosis (see General disorders). 
Valvularna fibroza (glejte Splošne težave).
Section 4.8 Undesirable effects [This section should be amended to reflect the following wording] 
Poglavje 4.8 Neželeni učinki [To poglavje je treba spremeniti tako, da vsebuje naslednje besedilo.]
Treatment must not begin until after the patient has been examined for any pre-existing fibrotic conditions. 
Zdravljenje se ne sme začeti, dokler ni bila pri bolniku s pregledom ovržena možnost že obstoječih fibrotičnih stanj.
Section 4.1 Therapeutic indications [The wording of this section should be read as below] 
Poglavje 4.1 Terapevtske indikacije [Besedilo tega poglavja mora biti naslednje.]